Trial Profile
Phase III Study of ASP1941 - Open-label, Non-comparative Study to Assess the Long-term Safety, Tolerability and Efficacy of ASP1941 in Combination With an α-Glucosidase Inhibitor in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control With an α-Glucosidase Inhibitor Alone
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipragliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Astellas Pharma
- 01 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 11 May 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 24 Nov 2010 New trial record